Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
This appears to be nerve pain; tooth pain; Mouth pain; This non-serious case was reported by a consumer and described the occurrence of toothache in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 12-OCT-2024, the patient received Shingrix. On 23-NOV-2024, 42 days after receiving Shingrix, the patient experienced toothache (Verbatim: tooth pain) and oral pain (Verbatim: Mouth pain). On an unknown date, the patient experienced nerve pain (Verbatim: This appears to be nerve pain). The outcome of the toothache and oral pain were not resolved and the outcome of the nerve pain was not reported. It was unknown if the reporter considered the toothache, oral pain and nerve pain to be related to Shingrix. It was unknown if the company considered the toothache, oral pain and nerve pain to be related to Shingrix. Additional Information: GSK Receipt Date: 02-MAY-2025 The reporter reported that she had been experiencing excruciating pain in mouth and teeth. The reporter seen her dentist twice and there was no visible signs of tooth damage. This appears to be nerve pain that began after she was vaccinated with Shingrix. The reporter understanding was that trigeminal neuralgia could be a side effect of shingles. The reporter would like to speak with someone in medical information regarding this and know if there were any reports of this in the clinical trials or if it was looked for in the clinical protocols. The reporter had no history of having shingles. The symptoms were treated.